September 23, 2021 7:10pm

A scorecard of of 35 covered  companies and date of releases (to date). The current LPS (loss per share) or net income, cash positions i.e. "runways"  is a reflection of this universe's investing "status"

New addition: Applied Genetic Technologies (AGTC)

 

 


COMPANY 

SYMBOL NET INCOME Q2/21 LOSS Q2/21 LPS Q2/21 CASH RUNWAY
Chinook Therapeutics  KDNY

 

-$42.6 M -$0.97 $229.8 M 2H/2023
Alnylam Pharmaceuticals ALNY     -$189.5 M -$1.61 

$1.9 B

N/A
Applied Genetic Technologies AGTC  

-$12.1 M

Year end: -$57.8

 

-$0.28

-$1.77

 

$107.1 M Q1/23
Athersys, Inc. ATHX       -$22.6 M -$0.10

$56.7 M

Q1/2023
Adverum Biotechnologies, Inc. ADVM   -$44.3 M -$0.45

$363.8 M

2024
AxoGen, Inc. AXGN      -$7.9 M

-$0.19

 

$106.2 M  2024
Bellicum Pharmaceuticals BLCM

 

-$2.2 M

-$0.22

$21.8 M 2022
BioLife Solutions, Inc. BLFS

+$7.9 M or 

+$0.19 per share

 

 

 

 

$76.3 M

2024
Biostage, Inc. BSTG   -$382 K -$0.04

$451 K

Q2/2021
bluebird bio BLUE     Splits into two (2) companies   -$241.7 M $3.58 

$942 M

2024
Brainstorm Cell Therapeutics BCLI   -$6.3 M -$0.17

 

$35 M

1st H/2022
Caladrius Biosciences. CLBS    -$5.68 M -$0.10

$106.1 M

2024

Cellectis SA CLLS  

 

-$40 M -$0.88

$257 M

2024

CRISPR Therapeutics

 

CRSP

+$759.2 M or 

+$10.01 per share

    +$2.589.4 M N/A

Editas Medicine

 

EDIT      -$55.3 M -$0.81 $698.1 M 2023
Fate Therapeutics

FATE    

 

  -$54.9 M  -$0.58 $845.1 M 2024

Global Blood Therapeutics

 

GBT      -$69.6 M -$1.12 $437.4 M 2024

Homology Medicine

 

FIXX   -$30.5 M -$0.54 $213.3 M Q1/2023

Intellia Therapeutics

 

NTLA   -$68.8 M -$1.01 $551 M 2023

Precigen

formerly

Intrexon Corporation

PGEN   $41.9 M -$0.21 $200.4 M 2H//2023
Ionis Pharmaceuticals IONS

 

 

-$81 M -$0.57 $2.1 B N/A
Mesoblast Limited MESO  

 

 

 

/20
MiMedx Group, Inc

MDXG    

 

-$1.8 M -$0.08 $85 M 2023
Pluristem Therapeutics, Inc.

PSTI

 

        Q1/2022
ReNeuron Group PLC

RENE.L

 

         
Regenxbio

RGNX

 

  -$57.6 M -$1.36 $530 M 2H/2023
Sage Therapeutics

SAGE

 

  -$1.7.2 M -$1.83 $1.9B N/A
Sangamo Biosciences, Inc.

SGMO 

 

  -$47.2 M -$0.33 $578.9 M 2024
Solid Biosciences SLDB  

-$18.7 M

Not disclosed $249 M Q4/22
Stemline Therapeutics, Inc. STML

Acquired by

Menarini, an

Italian pharma

       

Ultragenyx

 

RARE      -$122.4 M -$1.81 $973.8 M 2025

uniQure N.V.

 

QURE  

Net income: +$399.5 M or

+$8.68 per share

 

  $677.3 million 1st Half/24

Verastem, Inc.

 

VSTM   -$16.9 M -$0.10 $114.1 M 2024

Vericel Corporation

 

VCEL     -$3.8 M -$0.08 $116 M 2024
Voyager Therapeutics VYGR

 

 

-$30.12 -$0.80 $143 M Q2/2023